SMAD7 and Cowden disease: Phase 1 and phase 2 studies showed that knockdown of Smad7 with a pharmaceutical compound containing the Smad7 AS induced clinical and endoscopic improvement in CD patients, [17, 18] even though a recent phase 3 study was discontinued following a futility analysis showing no benefit in patients treated with such a drug as compared to those receiving placebo.